196 related articles for article (PubMed ID: 15280922)
1. Nitrogen-containing bisphosphonates inhibit cell cycle progression in human melanoma cells.
Forsea AM; Müller C; Riebeling C; Orfanos CE; Geilen CC
Br J Cancer; 2004 Aug; 91(4):803-10. PubMed ID: 15280922
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates induce breast cancer cell death in vitro.
Fromigue O; Lagneaux L; Body JJ
J Bone Miner Res; 2000 Nov; 15(11):2211-21. PubMed ID: 11092402
[TBL] [Abstract][Full Text] [Related]
3. In vitro toxicity of bisphosphonates on human neuroblastoma cell lines.
Vorotnjak M; Boos J; Lanvers-Kaminsky C
Anticancer Drugs; 2004 Sep; 15(8):795-802. PubMed ID: 15494642
[TBL] [Abstract][Full Text] [Related]
4. The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes--in vitro study.
Pabst AM; Ziebart T; Koch FP; Taylor KY; Al-Nawas B; Walter C
Clin Oral Investig; 2012 Feb; 16(1):87-93. PubMed ID: 21225298
[TBL] [Abstract][Full Text] [Related]
5. In vitro effects of bisphosphonates on chemotaxis, phagocytosis, and oxidative burst of neutrophil granulocytes.
Hagelauer N; Pabst AM; Ziebart T; Ulbrich H; Walter C
Clin Oral Investig; 2015 Jan; 19(1):139-48. PubMed ID: 24668343
[TBL] [Abstract][Full Text] [Related]
6. Pilot studies of the effect of zoledronic acid (Zometa) on tumor-derived cells ex vivo in the ATP-based tumor chemosensitivity assay.
Knight LA; Conroy M; Fernando A; Polak M; Kurbacher CM; Cree IA
Anticancer Drugs; 2005 Oct; 16(9):969-76. PubMed ID: 16162973
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonates affect migration ability and cell viability of HUVEC, fibroblasts and osteoblasts in vitro.
Walter C; Pabst A; Ziebart T; Klein M; Al-Nawas B
Oral Dis; 2011 Mar; 17(2):194-9. PubMed ID: 20796232
[TBL] [Abstract][Full Text] [Related]
8. The bisphosphonate pamidronate induces apoptosis in human melanoma cells in vitro.
Riebeling C; Forsea AM; Raisova M; Orfanos CE; Geilen CC
Br J Cancer; 2002 Jul; 87(3):366-71. PubMed ID: 12177810
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro.
Ziebart T; Pabst A; Klein MO; Kämmerer P; Gauss L; Brüllmann D; Al-Nawas B; Walter C
Clin Oral Investig; 2011 Feb; 15(1):105-11. PubMed ID: 20024592
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates induce apoptosis in human breast cancer cell lines.
Senaratne SG; Pirianov G; Mansi JL; Arnett TR; Colston KW
Br J Cancer; 2000 Apr; 82(8):1459-68. PubMed ID: 10780527
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.
Shipman CM; Rogers MJ; Apperley JF; Russell RG; Croucher PI
Br J Haematol; 1997 Sep; 98(3):665-72. PubMed ID: 9332325
[TBL] [Abstract][Full Text] [Related]
12. The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro.
Sonnemann J; Eckervogt V; Truckenbrod B; Boos J; Winkelmann W; van Valen F
Anticancer Drugs; 2001 Jun; 12(5):459-65. PubMed ID: 11395574
[TBL] [Abstract][Full Text] [Related]
13. The cell cycle arrest and the anti-invasive effects of nitrogen-containing bisphosphonates are not mediated by DBF4 in breast cancer cells.
Mansouri M; Mirzaei SA; Lage H; Mousavi SS; Elahian F
Biochimie; 2014 Apr; 99():71-6. PubMed ID: 24287290
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases.
Boissier S; Ferreras M; Peyruchaud O; Magnetto S; Ebetino FH; Colombel M; Delmas P; Delaissé JM; Clézardin P
Cancer Res; 2000 Jun; 60(11):2949-54. PubMed ID: 10850442
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts.
Fromigué O; Body JJ
J Endocrinol Invest; 2002 Jun; 25(6):539-46. PubMed ID: 12109626
[TBL] [Abstract][Full Text] [Related]
16. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates.
Aparicio A; Gardner A; Tu Y; Savage A; Berenson J; Lichtenstein A
Leukemia; 1998 Feb; 12(2):220-9. PubMed ID: 9519785
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth.
Mönkkönen H; Kuokkanen J; Holen I; Evans A; Lefley DV; Jauhiainen M; Auriola S; Mönkkönen J
Anticancer Drugs; 2008 Apr; 19(4):391-9. PubMed ID: 18454049
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonates in multiple myeloma: a network meta-analysis.
Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
[TBL] [Abstract][Full Text] [Related]
19. Effect of bisphosphonates on the rapidly growing male murine skeleton.
Zhu ED; Louis L; Brooks DJ; Bouxsein ML; Demay MB
Endocrinology; 2014 Apr; 155(4):1188-96. PubMed ID: 24422540
[TBL] [Abstract][Full Text] [Related]
20. Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt.
Bezzi M; Hasmim M; Bieler G; Dormond O; Rüegg C
J Biol Chem; 2003 Oct; 278(44):43603-14. PubMed ID: 12933798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
